A Study of LY3471851 in Participants With Eczema

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Inclusion Criteria:

• Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months
• Have active AD according to study specific criteria
• Be willing and able to undergo skin biopsies

Exclusion Criteria:

• Have received certain topical medications for AD within 14 days prior to baseline
• Have received certain systemic medications for AD within 4 weeks prior to baseline
• Have received LY3471851 previously